What is Dyax Financial Strength?
Dyax has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Dyax did not have earnings to cover the interest expense.
Dyax's debt to revenue ratio for the quarter that ended in Sep. 2015 was 0.00.
As of today, Dyax's Altman Z-Score is 0.00.
Competitive Comparison of Dyax's Financial Strength
For the Biotechnology subindustry, Dyax's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dyax's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dyax's Financial Strength distribution charts can be found below:
* The bar in red indicates where Dyax's Financial Strength falls into.
Dyax Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Dyax's Interest Expense for the
months ended in Sep. 2015 was $-3.43 Mil. Its Operating Income for the
months ended in Sep. 2015 was $-8.49 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $0.00 Mil.
Dyax's Interest Coverage for the quarter that ended in Sep. 2015 is
| Dyax did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Dyax's Debt to Revenue Ratio for the quarter that ended in Sep. 2015 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Dyax has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyax (DYAX) Business Description
Traded in Other Exchanges
N/A
Address
Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.
Executives
| David J Mclachlan |
other: Former director |
ONE KENDALL SQUARE, CAMBRIDGE MA 02139 |
| Gustav Christensen |
officer: CEO and President, other: Former director |
DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Todd Bazemore |
officer: EVP & Chief Commercial Officer |
C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Thomas L Kempner |
other: Former director |
C/O LOEB PARTNERS CORPORATION, 125 BROAD STREET, 14TH FLOOR, NEW YORK NY 10004 |
| Abbie Celniker |
other: Former director |
C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142 |
| Marc D Kozin |
other: Former director |
|
| Andrew D. Ashe |
officer: General Counsel & EVP |
C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Ron Cohen |
other: Former director |
C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
| Mary Ann Gray |
other: Former director |
201 W 70TH ST, SUITE 23K, NEW YORK NY 10023 |
| George V Migausky |
officer: EVP & Chief Financial Officer |
C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Paolo Pucci |
other: Former director |
C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
| Burt A Adelman |
officer: CMO & EVP, R&D |
DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
| Ivana Magovcevic-liebisch |
officer: EVP; Chief Operating Officer |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Susan B Bayh |
director |
WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
| Stephen S Galliker |
officer: EVP and CFO |
300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DYAX has been successfully added to your